{"component": "definition", "props": {"groups": [{"samples": [{"hash": "1hyUN4FkJSF", "uri": "https://www.sec.gov/Archives/edgar/data/882796/000117184321001411/ex_230714.htm", "label": "Purchase and Sale Agreement (Biocryst Pharmaceuticals Inc)", "score": 23.1622180939, "published": false}, {"hash": "grWJizmy1Gg", "uri": "https://www.sec.gov/Archives/edgar/data/882796/000117184322001460/ex_340700.htm", "label": "Purchase and Sale Agreement (Biocryst Pharmaceuticals Inc)", "score": 21.1587944031, "published": false}], "snippet_links": [{"key": "the-products", "type": "clause", "offset": [54, 66]}, {"key": "all-inventory", "type": "clause", "offset": [78, 91]}, {"key": "product-rights", "type": "definition", "offset": [118, 132]}, {"key": "by-the-seller", "type": "clause", "offset": [167, 180]}, {"key": "all-accounts-receivable", "type": "clause", "offset": [243, 266]}, {"key": "general-intangibles", "type": "definition", "offset": [271, 290]}, {"key": "the-sale", "type": "clause", "offset": [306, 314]}, {"key": "disposition-of-products", "type": "clause", "offset": [333, 356]}], "size": 9, "snippet": "means the Seller\u2019s rights, title and interests in (a) the Products (including all inventory of the Products), (b) the Product Rights owned, licensed or otherwise held by the Seller, and (c) any proceeds from either (a) or (b) above, including all accounts receivable and general intangibles resulting from the sale, license or other disposition of Products by the Seller or its Licensees.", "hash": "39ff73ad3158b2a80b508415eabe5974", "id": 1}, {"samples": [{"hash": "267TZdtoa7b", "uri": "/contracts/267TZdtoa7b#product-collateral", "label": "Transitional Trademark Cross License Agreement (Solventum Corp)", "score": 35.2559890747, "published": true}, {"hash": "eTN25yxBPJ3", "uri": "/contracts/eTN25yxBPJ3#product-collateral", "label": "Transitional Trademark Cross License Agreement (Solventum Corp)", "score": 35.1765899658, "published": true}, {"hash": "bXhwV6uDeeL", "uri": "/contracts/bXhwV6uDeeL#product-collateral", "label": "Transitional Trademark Cross License Agreement (Solventum Corp)", "score": 35.1355247498, "published": true}], "snippet_links": [{"key": "social-media-content", "type": "definition", "offset": [57, 77]}, {"key": "marketing-materials", "type": "clause", "offset": [107, 126]}, {"key": "licensed-product", "type": "definition", "offset": [164, 180]}], "size": 4, "snippet": "means digital and printed brochures, catalogs, websites, social media content, displays, images, and other marketing materials that are specific to or describe any Licensed Product.", "hash": "f9451adb2a3461422ef4f1dff84fcaad", "id": 2}, {"samples": [{"hash": "ffFxsuJmKYr", "uri": "/contracts/ffFxsuJmKYr#product-collateral", "label": "Loan and Security Agreement", "score": 31.3408622742, "published": true}, {"hash": "frCqGlkyB3R", "uri": "/contracts/frCqGlkyB3R#product-collateral", "label": "Loan and Security Agreement (Sunesis Pharmaceuticals Inc)", "score": 27.35181427, "published": true}, {"hash": "9kGuNgDc2co", "uri": "/contracts/9kGuNgDc2co#product-collateral", "label": "Loan and Security Agreement (Sunesis Pharmaceuticals Inc)", "score": 23.3682403564, "published": true}], "snippet_links": [{"key": "the-product", "type": "clause", "offset": [6, 17]}, {"key": "revenue-participation-agreement", "type": "definition", "offset": [47, 78]}], "size": 4, "snippet": "means the Product Collateral as defined in the Revenue Participation Agreement.", "hash": "0fe7f640db78378e21a9ed6d0cd09c0b", "id": 3}, {"samples": [{"hash": "eawdYbmZv5E", "uri": "/contracts/eawdYbmZv5E#product-collateral", "label": "Revenue Participation Agreement", "score": 31.3408622742, "published": true}, {"hash": "3I23JpkGSUR", "uri": "/contracts/3I23JpkGSUR#product-collateral", "label": "Revenue Participation Agreement (Sunesis Pharmaceuticals Inc)", "score": 23.3682403564, "published": true}, {"hash": "iURhfiddELH", "uri": "http://ir.sunesis.com/static-files/126673dc-1517-494a-bfdc-34b989f74209", "label": "ir.sunesis.com", "score": 10.1704311371, "published": false}], "snippet_links": [{"key": "vosaroxin-product-rights", "type": "definition", "offset": [37, 61]}, {"key": "by-the-seller", "type": "clause", "offset": [80, 93]}, {"key": "accounts-and-general-intangibles", "type": "clause", "offset": [134, 166]}, {"key": "license-of-products", "type": "clause", "offset": [194, 213]}], "size": 3, "snippet": "means the Seller\u2019s interest in those Vosaroxin Product Rights owned or licensed by the Seller and any proceeds thereof, including all accounts and general intangibles resulting from the sale or license of Products by the Seller.", "hash": "f8c1518a107395c9da8058ca3b1c2382", "id": 4}, {"samples": [{"hash": "lLbkgIL5BRR", "uri": "/contracts/lLbkgIL5BRR#product-collateral", "label": "Purchase and Sale Agreement (Avadel Pharmaceuticals PLC)", "score": 34.2402458191, "published": true}, {"hash": "bcO2X2HOSbx", "uri": "https://investors.avadel.com/static-files/bec4f0d0-1a3b-48f8-b6f3-fedbe313b0cd", "label": "investors.avadel.com", "score": 11.7008895874, "published": false}], "snippet_links": [{"key": "royalty-payments", "type": "clause", "offset": [76, 92]}, {"key": "the-products", "type": "clause", "offset": [98, 110]}, {"key": "all-inventory", "type": "clause", "offset": [122, 135]}, {"key": "product-rights", "type": "definition", "offset": [162, 176]}, {"key": "by-the-parent", "type": "clause", "offset": [211, 224]}, {"key": "all-accounts-receivable", "type": "clause", "offset": [320, 343]}, {"key": "general-intangibles", "type": "definition", "offset": [348, 367]}, {"key": "the-sale", "type": "clause", "offset": [383, 391]}, {"key": "disposition-of-products", "type": "clause", "offset": [410, 433]}, {"key": "by-the-seller", "type": "clause", "offset": [434, 447]}], "size": 2, "snippet": "means Parent\u2019s and its Subsidiaries\u2019 rights, title and interests in (a) the Royalty Payments; (b) the Products (including all inventory of the Products), (c) the Product Rights owned, licensed or otherwise held by the Parent of any of its Subsidiaries, and (d) any proceeds from either (a), (b), or (c) above, including all accounts receivable and general intangibles resulting from the sale, license or other disposition of Products by the Seller, its Affiliates, or its Licensees.", "hash": "351d2dad659dde38e7fd46b3e0f6697f", "id": 5}, {"samples": [{"hash": "36pMGjmXVPy", "uri": "/contracts/36pMGjmXVPy#product-collateral", "label": "Note Purchase Agreement (Revance Therapeutics, Inc.)", "score": 33.3531837463, "published": true}, {"hash": "6XJWnZnXT9o", "uri": "/contracts/6XJWnZnXT9o#product-collateral", "label": "Note Purchase Agreement (Revance Therapeutics, Inc.)", "score": 32.8507881165, "published": true}], "snippet_links": [{"key": "all-inventory", "type": "clause", "offset": [70, 83]}, {"key": "product-rights", "type": "definition", "offset": [102, 116]}, {"key": "by-the-issuer", "type": "clause", "offset": [151, 164]}, {"key": "the-foregoing", "type": "definition", "offset": [224, 237]}, {"key": "all-accounts-receivable", "type": "clause", "offset": [268, 291]}, {"key": "general-intangibles", "type": "definition", "offset": [296, 315]}, {"key": "the-sale", "type": "clause", "offset": [331, 339]}, {"key": "disposition-of", "type": "clause", "offset": [358, 372]}], "size": 2, "snippet": "means the Issuer\u2019s rights, title and interests in (a) Daxi (including all inventory of Daxi), (b) the Product Rights owned, licensed or otherwise held by the Issuer, and (c) any proceeds from property described in either of the foregoing clauses (a) or (b), including all accounts receivable and general intangibles resulting from the sale, license or other disposition of Daxi by the Issuer or its Licensees.", "hash": "a8098092b1c74e50293318714569f5c6", "id": 6}, {"samples": [{"hash": "buy6JqIfJkL", "uri": "/contracts/buy6JqIfJkL#product-collateral", "label": "Purchase and Sale Agreement (Candel Therapeutics, Inc.)", "score": 37.1916503906, "published": true}], "snippet_links": [{"key": "in-the-territory", "type": "clause", "offset": [119, 135]}, {"key": "royalty-payments", "type": "clause", "offset": [145, 161]}, {"key": "revenue-participation-right", "type": "definition", "offset": [170, 197]}, {"key": "the-products", "type": "clause", "offset": [203, 215]}, {"key": "all-inventory", "type": "clause", "offset": [227, 240]}, {"key": "for-sale", "type": "definition", "offset": [266, 274]}, {"key": "product-rights", "type": "definition", "offset": [302, 316]}, {"key": "by-the-seller", "type": "clause", "offset": [351, 364]}, {"key": "all-accounts-receivable", "type": "clause", "offset": [459, 482]}, {"key": "general-intangibles", "type": "definition", "offset": [487, 506]}, {"key": "the-sale", "type": "clause", "offset": [522, 530]}, {"key": "disposition-of-products", "type": "clause", "offset": [549, 572]}], "size": 2, "snippet": "means the Seller\u2019s or any of its Affiliate\u2019s rights, title and interests in any and all of the following as they exist in the Territory: (a) the Royalty Payments and the Revenue Participation Right; (b) the Products (including all inventory of the Products intended for sale in the Territory), (c) the Product Rights owned, licensed or otherwise held by the Seller, and (d) any \u201cproceeds\u201d (as defined in the UCC) from either (a), (b), or (c) above, including all accounts receivable and general intangibles resulting from the sale, license or other disposition of Products in the Territory by the Seller, its Affiliates, or its Licensees.", "hash": "cb830da9c220d2a8a2ca980d9cc618a2", "id": 7}, {"samples": [{"hash": "ZWaHVbTTBe", "uri": "/contracts/ZWaHVbTTBe#product-collateral", "label": "Working Interest Agreement (Vivakor, Inc.)", "score": 32.1156730652, "published": true}], "snippet_links": [{"key": "by-the-company", "type": "clause", "offset": [49, 63]}, {"key": "gross-revenue", "type": "definition", "offset": [106, 119]}, {"key": "net-revenue", "type": "clause", "offset": [123, 134]}], "size": 2, "snippet": "means any and all Product that has not been sold by the Company and therefore has not been converted into Gross Revenue or Net Revenue.", "hash": "fa5ace0d3608b28597852af832bd0cf7", "id": 8}, {"samples": [{"hash": "k2r1w1b6g0C", "uri": "/contracts/k2r1w1b6g0C#product-collateral", "label": "Credit Agreement (Biocryst Pharmaceuticals Inc)", "score": 32.1622161865, "published": true}], "snippet_links": [{"key": "royalty-financing-agreement", "type": "definition", "offset": [62, 89]}, {"key": "effect-on-the", "type": "clause", "offset": [96, 109]}, {"key": "date-hereof", "type": "clause", "offset": [110, 121]}], "size": 2, "snippet": "means the \u201cProduct Collateral\u201d as such term is defined in the Royalty Financing Agreement as in effect on the date hereof.", "hash": "fdd6cf8f518b9a015fcf9e005906090f", "id": 9}, {"samples": [{"hash": "1I8wua20K6W", "uri": "/contracts/1I8wua20K6W#product-collateral", "label": "Funding Agreement (Biohaven Pharmaceutical Holding Co Ltd.)", "score": 29.8555774689, "published": true}], "snippet_links": [{"key": "product-rights", "type": "definition", "offset": [74, 88]}, {"key": "by-the-seller", "type": "clause", "offset": [123, 136]}, {"key": "all-accounts-receivable", "type": "clause", "offset": [198, 221]}, {"key": "general-intangibles", "type": "definition", "offset": [226, 245]}, {"key": "the-sale", "type": "clause", "offset": [261, 269]}, {"key": "disposition-of-products", "type": "clause", "offset": [288, 311]}, {"key": "seller-entity", "type": "definition", "offset": [319, 332]}, {"key": "permitted-licensees", "type": "definition", "offset": [340, 359]}, {"key": "upon-a-change-of-control", "type": "clause", "offset": [386, 410]}, {"key": "acquiring-entity", "type": "definition", "offset": [474, 490]}, {"key": "prior-to-the-closing", "type": "clause", "offset": [618, 638]}, {"key": "in-the-case-of-an", "type": "clause", "offset": [669, 686]}, {"key": "acquired-affiliate", "type": "definition", "offset": [687, 705]}, {"key": "claiming-priority", "type": "clause", "offset": [782, 799]}, {"key": "other-intellectual-property-rights", "type": "clause", "offset": [835, 869]}, {"key": "rights-included", "type": "clause", "offset": [905, 920]}, {"key": "for-the-purposes-of", "type": "clause", "offset": [980, 999]}], "size": 2, "snippet": "means the Seller\u2019s and its Affiliates\u2019 rights, title and interests in the Product Rights owned, licensed or otherwise held by the Seller or any of its Affiliates and any proceeds thereof, including all accounts receivable and general intangibles resulting from the sale, license or other disposition of Products by any Seller Entity or its Permitted Licensees; provided, however, that, upon a Change of Control, no Product Rights owned, in-licensed or otherwise held by the acquiring entity (or any of its Affiliates existing prior to such Change of Control or acquired after such Change of Control) as of immediately prior to the closing of such Change of Control (or in the case of an acquired Affiliate, as of immediately prior to the closing of such acquisition) or any Patents claiming priority to any Patents included therein or other Intellectual Property Rights derived from Intellectual Property Rights included therein will be deemed \u201cowned, licensed or otherwise held\u201d for the purposes of this definition.", "hash": "34a33310b1461e4401aa31e88a935c6a", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIbcHJvZHVjdC1jb2xsYXRlcmFsIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Product Collateral", "size": 42, "snippet": "means the Seller\u2019s rights, title and interests in (a) the Products (including all inventory of the Products), (b) the Product Rights owned, licensed or otherwise held by the Seller, and (c) any proceeds from either (a) or (b) above, including all accounts receivable and general intangibles resulting from the sale, license or other disposition of Products by the Seller or its Licensees.", "id": "product-collateral", "examples": ["After the Amendment Date, the Seller shall use its Commercially Reasonable Efforts to obtain and maintain any required consents, acknowledgements, certificates or waivers so that the transactions contemplated by this Agreement or any other Transaction Document may be consummated and shall not result in any default or breach or termination of any material contract in respect of the Revenue Participation Right or the <strong>Product Collateral</strong>.", "None of the <strong>Product Collateral</strong> is subject to any Lien, except for \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587 and \u2587\u2587\u2587\u2587\u2587 created hereunder as of the Closing Date.", "The claims and rights of Buyer created by this Agreement in and to the Revenue Participation Right and any other <strong>Product Collateral</strong> are not subordinated in right of payment to any creditor of the Seller or any other Person (except to the extent specified in any Acceptable Intercreditor Agreement)."], "related": [["patent-collateral", "Patent Collateral", "Patent Collateral"], ["ucc-collateral", "UCC Collateral", "UCC Collateral"], ["security-agreement-collateral", "Security Agreement Collateral", "Security Agreement Collateral"], ["abl-collateral", "ABL Collateral", "ABL Collateral"], ["possessory-collateral", "Possessory Collateral", "Possessory Collateral"]], "related_snippets": [], "updated": "2026-03-22T04:42:52+00:00"}, "json": true, "cursor": ""}}